Literature DB >> 11906993

Fibrinolytic treatment for elderly patients with acute myocardial infarction.

J M Estess, E J Topol.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11906993      PMCID： PMC1767054          DOI： 10.1136/heart.87.4.308

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  29 in total

1.  Thrombolytic therapy in older patients.

Authors:  A K Berger; M J Radford; Y Wang; H M Krumholz
Journal:  J Am Coll Cardiol       Date:  2000-08       Impact factor: 24.094

2.  Thrombolytic therapy for elderly patients.

Authors:  E J Topol; R M Califf
Journal:  N Engl J Med       Date:  1992-07-02       Impact factor: 91.245

3.  The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and The International Study Group.

Authors:  A P Maggioni; M G Franzosi; E Santoro; H White; F Van de Werf; G Tognoni
Journal:  N Engl J Med       Date:  1992-07-02       Impact factor: 91.245

4.  Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project.

Authors:  L M Brass; J H Lichtman; Y Wang; J H Gurwitz; M J Radford; H M Krumholz
Journal:  Stroke       Date:  2000-08       Impact factor: 7.914

5.  Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI).

Authors: 
Journal:  Lancet       Date:  1986-02-22       Impact factor: 79.321

6.  Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction.

Authors:  R M Califf; E J Topol; B S George; J M Boswick; C Abbottsmith; K N Sigmon; R Candela; R Masek; D Kereiakes; W W O'Neill
Journal:  Am J Med       Date:  1988-09       Impact factor: 4.965

7.  ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1992-03-28       Impact factor: 79.321

8.  Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1988-08-13       Impact factor: 79.321

9.  GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.

Authors: 
Journal:  Lancet       Date:  1990-07-14       Impact factor: 79.321

10.  Prognostic significance of the extent of myocardial injury in acute myocardial infarction treated by streptokinase (the GISSI trial).

Authors:  F Mauri; M Gasparini; L Barbonaglia; E Santoro; M Grazia Franzosi; G Tognoni; F Rovelli
Journal:  Am J Cardiol       Date:  1989-06-01       Impact factor: 2.778
View more
  1 in total

1.  Explaining the increase in coronary heart disease mortality in Syria between 1996 and 2006.

Authors:  Samer Rastam; Radwan Al Ali; Wasim Maziak; Fawaz Mzayek; Fouad M Fouad; Martin O'Flaherty; Simon Capewell
Journal:  BMC Public Health       Date:  2012-09-09       Impact factor: 3.295
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.